Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -475.96% is 59% above its 1-year average of -1167.79%, near the high end of its 1-year range (-2415.37%–-150.10%).
59.24% above its 12-month average of -1167.79%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -620.89%.
EBITDA MARGIN
-475.96%
EBITDA MARGIN AVG TTM
-1167.79%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+59.24%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
LENZ Therapeutics, Inc.
Market Cap
$118.05M
EBITDA Margin
-475.96%
TTM Avg
-1167.79%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$117.03M
EBITDA Margin
-1187.82%
TTM Avg
-1407.84%
3Y Avg
-970.99%
5Y Avg
-809.42%
Market Cap
$116.82M
EBITDA Margin
-254.71%
TTM Avg
-369.64%
3Y Avg
-290.17%
5Y Avg
-290.17%
Market Cap
$116.14M
EBITDA Margin
-408000.00%
TTM Avg
-396456.25%
3Y Avg
-201636.71%
5Y Avg
-201636.71%
Market Cap
$115.93M
EBITDA Margin
-1036.29%
TTM Avg
-1034.54%
3Y Avg
-4587.22%
5Y Avg
-4766.38%
Market Cap
$115.77M
EBITDA Margin
-29.32%
TTM Avg
-13.32%
3Y Avg
-6.17%
5Y Avg
-1.07%
Market Cap
$121.23M
EBITDA Margin
-445.98%
TTM Avg
-559.71%
3Y Avg
-600.34%
5Y Avg
-1391.92%
Market Cap
$121.75M
EBITDA Margin
-1691.15%
TTM Avg
-1668.02%
3Y Avg
-8474.77%
5Y Avg
-5696.48%
Market Cap
$114.20M
EBITDA Margin
-254.86%
TTM Avg
-347.69%
3Y Avg
-398.28%
5Y Avg
-4102.41%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $118.05M | -475.96% | -1167.79% | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.03M | -1187.82% | -1407.84% | -970.99% | -809.42% |
| Coya Therapeutics, Inc. (COYA)vs › | $116.82M | -254.71% | -369.64% | -290.17% | -290.17% |
| Genelux Corporation (GNLX)vs › | $116.14M | -408000.00% | -396456.25% | -201636.71% | -201636.71% |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.93M | -1036.29% | -1034.54% | -4587.22% | -4766.38% |
| BGM Group Ltd. (BGM)vs › | $115.77M | -29.32% | -13.32% | -6.17% | -1.07% |
| Seer, Inc. (SEER)vs › | $121.23M | -445.98% | -559.71% | -600.34% | -1391.92% |
| Cibus, Inc. (CBUS)vs › | $121.75M | -1691.15% | -1668.02% | -8474.77% | -5696.48% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $114.20M | -254.86% | -347.69% | -398.28% | -4102.41% |
| enGene Holdings Inc. (ENGN)vs › | $122.26M | N/A | N/A | N/A | N/A |
Gross Margin
90.1%
EBITDA Margin
-476.0%
Operating Margin
-477.5%
Net Margin
-586.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -620.89% |
| 2026-03-31 | -2315.83% |
| 2025-12-31 | -2415.37% |
| 2025-09-30 | -150.10% |
| 2025-06-30 | -336.76% |
